Denileukin Diftitox
Brand names: Lymphir · Active ingredient: Denileukin Diftitox
In short: LYMPHIR is indicated for the treatment of adult patients with relapsed or refractory Stage I-III cutaneous T-cell lymphoma (CTCL) after at least one prior systemic therapy.
What is Denileukin Diftitox used for?
LYMPHIR is indicated for the treatment of adult patients with relapsed or refractory Stage I-III cutaneous T-cell lymphoma (CTCL) after at least one prior systemic therapy.
âš Boxed warning (FDA's strongest warning)
Capillary leak syndrome (CLS), including life-threatening or fatal reactions, can occur in patients receiving LYMPHIR. Monitor patients for signs and symptoms of CLS during treatment. Withhold LYMPHIR until CLS resolves, or permanently discontinue based on severity
.
Denileukin Diftitox dosage
Prior to starting each treatment cycle, assess hepatic and renal function. If serum albumin is less than 3 g/dL, delay administration of LYMPHIR until serum albumin is greater than or equal to 3 g/dL
.
The recommended dosage of LYMPHIR is 9 mcg/kg/day actual body weight administered as an intravenous infusion over 60 minutes on Days 1 through 5 of a 21-day treatment cycle. Administer LYMPHIR until disease progression or unacceptable toxicity.
Administer premedications prior to starting a LYMPHIR infusion in Cycles 1 through 3, as outlined in Table 1, to reduce the risk of infusion-related reactions
.
Treatment
Cycle | Premedication | Dosage | Administration
Cycles 1-3
(optional thereafter) | Antipyretic | Oral acetaminophen 650 mg
or per local institutional
guidelines | At least 30 minutes
prior to infusion
Antihistamine | Diphenhydramine 25 mg
intravenously or other
antihistamine per local
institutional guidelines | At least 30 minutes
prior to infusion
Antiemetic | Per institutional guidelines | At least 30 minutes
prior to infusion
Hydration | 250 to 500 mL 0.9% Sodium
Chloride Injection
intravenously (or other
amount of fluid considered to
be most appropriate for the
subject’s condition) | At least 30 minutes
prior to infusion
If patients experience a Grade 2 or higher infusion reaction, premedicate at least 30 minutes prior to each subsequent infusion with a systemic steroid such as dexamethasone 4 mg (or equivalent) via slow intravenous push, for at least 3 cycles.
Dosage modifications for adverse reactions with LYMPHIR are shown in Table 2 below.
Adverse Reaction | Severity* | Dosage Modification
Capillary leak syndrome (CLS)
| Grade 2 | Withhold LYMPHIR until CLS resolves to Grade 1.
Grade 3 | Withhold LYMPHIR and provide supportive care until CLS resolves to Grade 1.
Resume LYMPHIR at 50% dose.
Consider steroid premedication for subsequent infusions.
Permanently discontinue upon recurrence.
Grade 4 | Permanently discontinue LYMPHIR.
Visual impairment
| Grade 1 or 2 | Consider withholding or discontinuing LYMPHIR as appropriate.
Refer for ophthalmic evaluation.
Grade 3 or 4 | Withhold LYMPHIR until resolved to Grade 1 or baseline.
Refer for ophthalmic evaluation.
Permanently discontinue LYMPHIR if impairment does not resolve to Grade 1 or baseline.
Infusion-related reactions
| Grade 2 or 3 | Interrupt infusion and manage signs and symptoms.
Administer steroid premedication prior to the subsequent doses of LYMPHIR
Continue steroid premedication for each dose in the next 3 cycles and optional thereafter
Grade 4 or
Recurrent
Grade 3 | Permanently discontinue LYMPHIR. …
How to take Denileukin Diftitox — instructions & advice from the label
Discuss the following with patients prior to and during treatment with LYMPHIR.
Capillary Leak Syndrome
Inform patients of the signs and symptoms of capillary leak syndrome. Advise patients to contact their healthcare provider immediately if any signs or symptoms of capillary leak syndrome occur, including edema or change in blood pressure. Instruct patients to weigh themselves daily and report weight gain
.
Visual Impairment
Inform patients that if they experience symptoms of visual impairment, such as changes in visual acuity, changes in color vision, or blurred vision, they should report it promptly
.
Infusion-Related Reactions
Inform patients of the signs and symptoms of infusion-related reactions. Advise patients to contact their healthcare provider immediately if any signs or symptoms of infusion-related reaction occur, including fever, chills, breathing problems, chest pain, or hives
.
Hepatotoxicity
Advise patients that liver enzyme elevations can occur and that they should report symptoms that may indicate liver toxicity, including fatigue, anorexia, right upper abdominal discomfort, dark urine, or jaundice
. …
Warnings & precautions
Do not take this medicine if: None.
LYMPHIR can cause capillary leak syndrome (CLS), including life-threatening or fatal reactions. CLS was defined in the clinical trials as the occurrence of at least 2 of the following symptoms at any time during LYMPHIR therapy: hypotension, edema, and serum albumin <3 g/dL. These symptoms were not required to occur simultaneously to be characterized as capillary leak syndrome.
As defined, CLS occurred in 27% of patients in the pooled population across 3 clinical trials, including 8% with Grade 3. There was one (0.8%) fatal occurrence of CLS. Of the patients with CLS, 22% had recurrence. The majority of CLS events (81%) occurred within the first 2 cycles of treatment. The median time to onset from Cycle 1, Day 1 was 6.5 days (range: 1 to 77), the median duration of CLS was 14 days (range: 2 to 40), and 75% of patients had resolution. The most common symptoms included edema, hypoalbuminemia, and hypotension. Pleural effusion, pericardial effusion, and dehydration also occurred.
Regularly assess patients for weight gain, new onset or worsening of edema, dyspnea, and hypotension (including orthostatic changes). Monitor serum albumin levels prior to the initiation of each cycle of therapy and more often as clinically indicated.
Withhold, reduce dose, or permanently discontinue based on severity. If LYMPHIR is withheld, resume LYMPHIR following resolution of CLS and when serum albumin is greater than or equal to 3 g/dL
.
LYMPHIR can cause serious visual impairment, including changes in visual acuity and color vision. In the pooled population across 3 clinical trials, visual impairment occurred in 9%, with Grade 1 in 8% and Grade 2 in 1%. The most commonly reported symptom was blurred vision. Of the patients with visual impairment, 67% had resolution of their visual impairment. …
Denileukin Diftitox side effects
The following adverse reactions are discussed in greater detail in other sections of the label:
Capillary Leak Syndrome
Visual Impairment
Infusion-Related Reactions
Hepatotoxicity
Because clinical trials are conducted under widely varying conditions, adverse reaction rates observed in the clinical trials of a drug cannot be directly compared to rates in the clinical trials of another drug and may not reflect the rates observed in practice.
The pooled safety population described in the WARNINGS AND PRECAUTIONS reflect exposure to LYMPHIR as a single agent in 119 patients with CTCL across 3 clinical trials. Patients received treatment with LYMPHIR as an intravenous infusion at 9 mcg/kg daily from Day 1 through Day 5 of each 21-day cycle until disease progression or unacceptable toxicity. Among 119 patients who received LYMPHIR the median number of cycles received was 5 (range: 1 to 42), with 13% exposed for 6 months or longer.
In this pooled safety population, the most common (≥ 20%) adverse reactions, including laboratory abnormalities, were increased transaminases (70%), albumin decreased (53%), nausea (40%), edema (35%), hemoglobin decreased (34%), fatigue (30%), musculoskeletal pain (26%), rash (23%), chills (22%), constipation (22%), pyrexia (21%), and capillary leak syndrome (20%). …
About this medicine
Denileukin diftitox-cxdl, an IL2-receptor-directed cytotoxin, is a recombinant DNA-derived fusion protein composed of the amino acid sequences for diphtheria toxin fragments A and B (Met
1-Thr
387)-His and the sequence for human interleukin-2 (IL-2; Ala
1-Thr
133). It is produced in an
E. coliexpression system and has a molecular weight of 58 kD. Neomycin is used in the fermentation process but is undetectable in the final product.
LYMPHIR (denileukin diftitox-cxdl) for injection is supplied as a sterile, white, lyophilized cake in a single-dose vial for intravenous use after reconstitution and dilution. Each vial of LYMPHIR contains 300 mcg of denileukin diftitox-cxdl, citric acid monohydrate (4.2 mg), edetate disodium (0.04 mg), methionine (3 mg), polysorbate 20 (1.2 mg), and trehalose (100.4 mg). Sodium hydroxide is used to adjust the pH of the formulation buffer. Following reconstitution with 2.1 mL of Sterile Water for Injection, USP, the resulting concentration of denileukin diftitox-cxdl is 150 mcg/mL at pH approximately 7. …
Source: FDA-approved label via DailyMed (U.S. National Library of Medicine), label set ID ac3613d7-4304-40e7-a3f5-adb8a8adca5d. Read the full official label on DailyMed.
Related medicines
Levothyroxine Allopurinol Ondansetron Finasteride Clonidine Testosterone Thyroid Methotrexate